文献速递毛发、甲与色素性疾病

美国白癜风患者经济负担:回顾性数据库理赔研究

Economic Burden among Patients with Vitiligo in the United States: A Retrospective Database Claims Study.
PubMed 文献 · J Invest Dermatol · 2023-09-20

该回顾性队列分析基于Merative MarketScan商业数据库,评估美国白癜风患者的医疗费用与医疗资源利用(HCRU)。白癜风患者与无白癜风对照按1:2匹配,随访1年。白癜风患者全因费用(15551美元 vs 7735美元)和白癜风相关费用(3490美元 vs 54美元)均显著高于对照(P < .0001),全因及心理健康相关HCRU也显著更高。

要点

  • 白癜风患者全因费用15551美元,显著高于对照7735美元(P < .0001)。
  • 白癜风相关费用3490美元,显著高于对照54美元(P < .0001)。
  • 全因及心理健康相关HCRU在白癜风患者中显著更高(P < .0001)。

核心结论

  • 白癜风患者的医疗费用和HCRU显著高于无白癜风对照。

研究设计与样本

  • 回顾性队列分析,使用Merative MarketScan商业数据库,白癜风患者(49512例)与无白癜风对照(99024例)按1:2匹配,索引后随访1年。

主要发现

  • 白癜风患者全因费用15551美元 vs 对照7735美元(P < .0001)。
  • 白癜风患者白癜风相关费用3490美元 vs 对照54美元(P < .0001)。
  • 白癜风患者全因HCRU和心理健康相关HCRU均显著高于对照(P < .0001)。
  • 接受全身性效应治疗或新发心理健康诊断的患者亚组中,全因和白癜风相关费用差异仍显著高于对照(P < .0001)。

临床怎么用

  • 该研究聚焦直接费用,未涉及间接费用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with vitiligo incur direct and indirect costs associated with their condition; however, data regarding the economic burden of vitiligo are scarce and outdated. In this retrospective cohort analysis of the Merative MarketScan Commercial Database, healthcare costs and healthcare resource utilization (HCRU) were evaluated among United States patients with vitiligo. Patients with vitiligo were matched (1:2) with individuals without vitiligo (controls) between January 2007 and December 2021. Outcomes included all-cause and vitiligo-related costs (2021 dollars) and all-cause HCRU, including mental health-related HCRU, during a 1-year postindex period. Subgroup analyses were completed for patients on vitiligo treatments with systemic effects (such as phototherapy and oral steroids) or a new mental health diagnosis. The analysis was focused solely on direct costs. Baseline demographics were well-balanced between matched vitiligo (49,512) and control (99,024) cohorts. Patients with vitiligo incurred significantly higher all-cause ($15,551 vs $7735) and vitiligo-related ($3490 vs $54) costs than controls (P < .0001). All-cause and mental health-related HCRU were also significantly higher among patients with vitiligo (P < .0001). Differences in all-cause and vitiligo-related healthcare costs remained significantly higher in patients on treatments with systemic effects/mental health diagnoses than in controls (P < .0001). Taken together, healthcare costs and HCRU were significantly higher among patients with vitiligo than among controls.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Ezzedine K, Soliman AM, Li C, et al. Economic Burden among Patients with Vitiligo in the United States: A Retrospective Database Claims Study. J Invest Dermatol. 2023. PMID: 37739338. doi:10.1016/j.jid.2023.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。